Morgan Stanley’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Morgan Stanley’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-500	Closed	-$224	–	7959
2022 Q4	$224	Hold	500	–	–	﹤0.01%	7633
2022 Q3	$0	Hold	500	–	–	﹤0.01%	8056
2022 Q2	$0	Sell	500 -12,161	-96%	-$5.89K	﹤0.01%	8151
2022 Q1	$8K	Sell	12,661 -42,875	-77%	-$22.5K	﹤0.01%	7482
2021 Q4	$38K	Buy	55,536 +41,233	+288%	+$73.5K	﹤0.01%	6940
2021 Q3	$49K	Sell	14,303 -396	-3%	-$1.24K	﹤0.01%	6739
2021 Q2	$56K	Buy	14,699 +8,862	+152%	+$36.6K	﹤0.01%	6627
2021 Q1	$36K	Sell	5,837 -3,244	-36%	-$28.7K	﹤0.01%	6509
2020 Q4	$71K	Buy	+9,081	New	+$83.3K	﹤0.01%	6041

Other funds holding MTCR

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Morgan Stanley's MTCR Position: Q1 2023 in Review

Morgan Stanley sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 500 shares — an estimated $224 sold.

Morgan Stanley first reported a position in MTCR in Q4 2020 and held it in 9 quarters. The position peaked at $71K in Q4 2020. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

Morgan Stanley reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Morgan Stanley sold 500 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $224.
Morgan Stanley first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
Morgan Stanley's Metacrine, Inc. Common Stock position peaked at $71K in Q4 2020.
5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.